Eucodis GmbH signs with Sandoz GmbH a collaboration agreement

EUCODIS GmbH announced today they have signed a collaboration agreement with Sandoz GmbH. EUCODIS will develop and produce an enzyme for one of Sandoz’ production processes. EUCODIS’ will thereby apply its unique in vivo recombination technology.
Financial terms were not disclosed.

“We are very pleased that we were again chosen by Sandoz for this important project which represents our second collaboration after the first one started in January 2007. The signature of this contract marks another important milestone in the development of our enzyme business. For the first time we will apply our technology portfolio and project expertise to completely develop and produce an enzyme. It further confirms EUCODIS strategy to become a product company with leading market positions in high value niche markets.”commented Rudy Pandjaitan, director of enzyme business unit.

EUCODIS GmbH is a biotechnology company, with headquarter and main laboratories at Vienna, Austria, and a subsidiary EUCODIS France at Paris, France. EUCODIS applying its unique technologies of in vivo recombination and somatic hypermutation generating projects and partnerships in two business areas: “red biotechnology”, focussing on (bio-)pharmaceuticals and human antibodies, and “white biotechnology” comprising projects partnered to leading life science companies on novel enzymes and fermentation optimisation. The outstanding quality and excellence of EUCODIS’ has recently been confirmed by successful industry collaborations, public awards and governmental grants. Additionally to the industry collaborations three internal projects in pharmaceuticals are currently in research phase and based on this successful internal development EUCODIS will thereby mature to a product driven research and development company.

For further information please contact:
Rudy Pandjaitan Director Enzyme Business Unit EUCODIS GmbH
Brunner Strasse 59 A-1230 Wien e-mail: office(at)

The sender takes full responsibility for the content of this news item. Content may include forward-looking statements which, at the time they were made, were based on expectations of future events. Readers are cautioned not to rely on these forward-looking statements.

As a life sciences organization based in Vienna, would you like us to promote your news and events? If so, please send your contributions to news(at)